New Zealand Gazette – 1997 – No. 99

Page 2329

✨ Health and Medicines Notices



21 AUGUST NEW ZEALAND GAZETTE 2329

Māori health

That the Transitional Health Authority develops, contracts for, and provides culturally effective systems and services which meet the special health needs, expectations, and aspirations of Māori, so Māori will have the opportunity to enjoy the same level of health as non-Māori.

Mental health

That the Transitional Health Authority, by focusing on improving the access to, and co-ordination of services, decreases the prevalence of mental illness and reduces the impact of mental disorders on consumers, their families, caregivers, and the general community.

Child health

That the Transitional Health Authority focuses on improving the coverage of services, in particular through targeting those who are in need of additional services, and through improving identifying cost effective services that contribute to improving the health status of children and adolescents. The Transitional Health Authority must also ensure that the Government’s policy of near universal access to free medical services for children under 6 years old continues.

4. Access and Standards

In order to achieve the Crown’s primary objectives, the Transitional Health Authority shall have regard to:

4.1 the particular characteristics, special needs, and cultural values of communities (in particular Māori, Pacific Islands’ people, and people with disabilities);

4.2 any coverage and/or terms of access to the services specified by the Crown; and

4.3 the standards (including ethical standards) that the Authority considers appropriate for those services, and subject to generally accepted clinical protocols.

Dated at Wellington this 11th day of August 1997.

HON. BILL ENGLISH, Minister of Health.

go5701

Medicines Act 1981

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act, and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Tablet 1 x 28 Tablets Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Menoprem 2.5 Continuous
Conjugated oestrogens 0.625 mg;
Tablet 2 x 28
medroxyprogesterone acetate 5 mg
Tablet 1 x 28 Tablets Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Menoprem 5
Conjugated oestrogens 0.625 mg;
Tablet 2 x 14
medroxyprogesterone acetate 5 mg
Urofolitropin 75 IU, 150 IU in 3 mL Injection, powder, Industria Farmaceutica Serono SpA., Rome, Italy; Laboratoires Serono SA., Aubonne, Switzerland and Serono Pharm SpA., Bari, Italy Metrodin HP
and diluent (sodium chloride 0.9 % w/v in 1 mL) diluent, ampoule
Conjugated oestrogens 0.625 mg, Tablet Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Premia 2.5 Continuous
medroxyprogesterone acetate 2.5 mg
Tablet 1 x 14 Tablets Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Premia 5
Conjugated oestrogens 0.625 mg;
Tablet 2 x 14
medroxyprogesterone acetate 5 mg
Conjugated oestrogens 0.625 mg, Tablet Wyeth Medical Ireland, Newbridge, County Kildare, Eire and Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Premia 5 Continuous
medroxyprogesterone acetate 5 mg
Didanosine 25 mg, 50 mg, 100 mg, 150 mg Tablets, chewable/ dispersible Bristol-Myers Squibb Co, Evansville, Indiana, United States of America Videx

Dated this 12th day of August 1997.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go5688



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa — PDF NZ Gazette 1997, No 99


NZLII — PDF NZ Gazette 1997, No 99




✨ LLM interpretation of page content

🏥 Notice to the Transitional Health Authority of the Crown’s Objectives for Health and Disability Services for 1997/98 (continued from previous page)

🏥 Health & Social Welfare
11 August 1997
Health and Disability Services, Crown Objectives, Transitional Health Authority, Māori health, Mental health, Child health, Access and Standards
  • HON. BILL ENGLISH, Minister of Health

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
12 August 1997
Medicines, Distribution, Consent, Medicines Act 1981, Wyeth, Serono, Bristol-Myers Squibb
  • G. R. BOYD, Chief Advisor, Regulation and Safety